Skip to content

Granted (in shares) at other companies

Wingstop logo
WingstopWING
0
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
1.5M-12.6%
LivaNova logo
LivaNovaLIVN
957.7K+31.3%
The Hanover Insurance Group logo
The Hanover Insurance GroupTHG
148.1K+5.5%
Genpact logo
GenpactG
0
Ondas, Inc.
 logo
Ondas, Inc. ONDS
7.4M+45.6%

Other financials

Income statement

See full
Revenue$4.1M+161%
Operating income-$41.8M-10.8%
Net income-$33.4M-479%
EPS (diluted)-$0.21-520%

Balance sheet

See full
Cash & equivalents$90.2M+301%
Total debt$68.9M+27.6%
Total equity$7.4M-96.9%
Total assets$886.0M+12.5%

Cash flow

See full
Operating cash flow-$42.7M-9.7%
CapEx$3.4M-77.1%
Free cash flow-$46.1M+14.5%

Valuation

See full
Market cap$1.61B-24.5%
Enterprise value$1.58B-28.0%
P/S147.3×-1,198×

Profitability

See full
Operating margin-1,701.6%-763pp
Net margin-2,062.4%-937pp
FCF margin-1,612.6%-752pp

Returns & leverage

See full
Return on equity-183.1%-443pp
Debt / equity9.3×+9.1×
Current ratio1.7×+1.2×

Where this comes from

Reported directly by PureCycle Technologies, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross.

The official record: PureCycle Technologies, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about PureCycle Technologies, Inc.'s granted (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is PureCycle Technologies, Inc.'s granted (in shares)?
PureCycle Technologies, Inc. (PCT) reported granted (in shares) of 253K in Q1 2026.
How has PureCycle Technologies, Inc.'s granted (in shares) changed year-over-year?
PureCycle Technologies, Inc.'s granted (in shares) increased by 13.5% year-over-year, from 223K to 253K.
What does granted (in shares) mean?
The total number of stock option shares granted to employees and directors during the reporting period. This metric provides insight into the company's equity-based incentive strategy and potential future dilution.